BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BP1002 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BP1002\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05190471-10938@assetmemo.bio
DTSTAMP:20261121T005344Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BP1002: Phase 1 readout est. (NCT05190471)
DESCRIPTION:BP1002\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Clinical T
 rial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia
  (AML)\nEstimated primary completion: March 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bp1002#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05190471
URL:https://assetmemo.bio/drug/bp1002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
